Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies (Q36272854)

13 August 2017

1 reference

title

Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies (English)

1 reference

13 August 2017

Murielle Mimeault

1

1 reference

PubMed ID

16195239

13 August 2017

Surinder K Batra

series ordinal

2

1 reference

PubMed ID

16195239

13 August 2017

language of work or name

English

0 references

publication date

29 September 2005

1 reference

13 August 2017

1 reference

13 August 2017

27

1 reference

13 August 2017

1

1 reference

13 August 2017

1-22

1 reference

13 August 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Hedgehog signalling in prostate regeneration, neoplasia and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Expression patterns of potential therapeutic targets in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Wnt signalling and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Interference with HH-GLI signaling inhibits prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Growth factors involved in prostate carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Programmed cell death and survival pathways in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

20-year outcomes following conservative management of clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Future directions in the treatment of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Epithelial stem cells in human prostate growth and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Prostate carcinogenesis and inflammation: emerging insights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Radical causes of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

CD133, a novel marker for human prostatic epithelial stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Primary cell cultures as models of prostate cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Identification of a stem cell candidate in the normal human prostate gland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Signaling through estrogen receptors modulates telomerase activity in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Immortalization of primary human prostate epithelial cells by c-Myc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Pten dose dictates cancer progression in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)-TGF-beta type II dominant negative receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

The role of alpha 6 beta 1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Molecular pathway for cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Metastatic properties of prostate cancer cells are controlled by VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Direct evidence that PTHrP expression promotes prostate cancer progression in bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Notch Signaling and ERK Activation Are Important for the Osteomimetic Properties of Prostate Cancer Bone Metastatic Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Myc confers androgen-independent prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

E-cadherin and beta-catenin are down-regulated in prostatic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Regulation of prostasin expression and function in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Growth and survival mechanisms associated with perineural invasion in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Hedgehog signaling promotes prostate xenograft tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Growth factors and epithelial-stromal interactions in prostate cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Androgen receptor involvement in the progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Interleukin-6 regulation of prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Expression and function of androgen receptor coactivators in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Local aromatase expression in human prostate is altered in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Sex steroid hormone metabolism and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Enzymes as modulators in malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Rapid signalling pathway activation by androgens in epithelial and stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Beta-catenin signaling in prostate cancer: an early perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Regulation of tumor angiogenesis by integrin-linked kinase (ILK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Linking beta-catenin to androgen-signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Androgen receptor signaling: mechanism of interleukin-6 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Interleukin-6 is an autocrine growth factor in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Dysregulated expression of MIC-1/PDF in human prostate tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Transforming growth factor-beta1 induced myofibroblasts regulate LNCaP cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Neuroendocrine cells in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Genistein alters growth factor signaling in transgenic prostate model (TRAMP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Is there a role for chemotherapy in prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Signaling for the caspases: their role in prostate cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Signaling mechanisms that mediate invasion in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Survivin mediates resistance to antiandrogen therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Anti‐proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down‐regulation and ceramide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cell-derived neural transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGI229

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGI229

1 reference

13 August 2017

1 reference

PubMed ID

16195239